25
Reversible inhibitors of human vesicular monoamine
transporter type 2
a
Genric name
Trade name
Deutetrabenazine
Austedo
Tetrabenazine
Xenazine
Valbenazine
Ingrezza
Hepatic
impairment
Contraindicated Contraindicated Maximum dose
of 40mg daily
with moderate
to severe
impairment
(Child-Pugh
score 7–15)
Renal impairment No information
available
No information
available
Use not
recommended
in severe renal
impairment (CrCl
<30 mL/min)
Common adverse
effect
Sedation Sedation,
depression,
extrapyramidal
effects, insomnia,
akathisia,
anxiety, nausea,
falls
Sedation
Effect of food on
bioavailability
Food effects
maximal
concentration.
Administer with
food. Swallow
tablets whole
and do not chew,
crush, or break.
Unaffected by
food
Can be taken
with or without
food. High fat
meals decreased
the C
max
and AUC
for valbenazine
but values
for the active
metabolite
(alpha-HTBZ) are
unchanged
a
This table includes information compiled from multiple sources. Detailed information on
issues such as dose regimen, dose adjustments, medication administration procedures,
handling precautions, and storage can be found in product labeling. It is recommended
that readers consult product labeling information for authoritative information on these
medications.
(cont'd)
